Spotlight on Internal Medicine

Leonard H. Calabrese, DO
Credits: 0.25 CME
Case Conundrums in COVID-19: A Patient Presenting to the ED With Mild COVID-19
Leonard H. Calabrese, DO
Vindico Medical Education

Case Conundrums in COVID-19: A Patient Presenting to the ED With Mild COVID-19

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: March 30, 2022
Expires: March 29, 2023
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is rheumatologists, hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, and other health care professionals involved in the management of patients hospitalized with COVID-19.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Evaluate the latest data regarding immune-based therapies, including glucocorticoids, JAK inhibitors, and other targeted therapies for the management of patients with COVID-19.
  • Recognize how variables such as disease severity, comorbidities, and immunologic endotypes may impact the management of patients with COVID-19.

Activity Description

In this 4-part Curbside Consults video series, experts from infectious disease, pulmonology, and rheumatology will review clinical cases across the spectrum of COVID-19 disease. Strategies will be discussed for the prevention and management of severe COVID-19–associated hyperinflammation and respiratory damage.

Statement of Educational Need

The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Targeted immunomodulatory treatments can reduce the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up to date on the latest evidence-based care and rapidly evolving treatment guidelines.

Faculty

Activity Chair
Leonard H. Calabrese, DO

Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Relevant Financial Disclosure:
Consultant: AbbVie, Bristol-Myers Squibb, Genentech, Gilead, GlaxoSmithKline, Lilly, Pfizer, Regeneron
Speaker Contracted by Ineligible Company: AbbVie, AstraZeneca, GlaxoSmithKline

Faculty
Phyllis C. Tien, MD

Associate Professor of Medicine
University of California, San Francisco
San Francisco VA Medical Center, Infectious Disease Section
San Francisco, CA

Relevant Financial Disclosure:
Independent Research Contractor (paid to institution): Gilead, Lilly, Merck

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: March 30, 2022
Expires: March 29, 2023
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is rheumatologists, hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, and other health care professionals involved in the management of patients hospitalized with COVID-19.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Evaluate the latest data regarding immune-based therapies, including glucocorticoids, JAK inhibitors, and other targeted therapies for the management of patients with COVID-19.
  • Recognize how variables such as disease severity, comorbidities, and immunologic endotypes may impact the management of patients with COVID-19.

Activity Description

In this 4-part Curbside Consults video series, experts from infectious disease, pulmonology, and rheumatology will review clinical cases across the spectrum of COVID-19 disease. Strategies will be discussed for the prevention and management of severe COVID-19–associated hyperinflammation and respiratory damage.

Statement of Educational Need

The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Targeted immunomodulatory treatments can reduce the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up to date on the latest evidence-based care and rapidly evolving treatment guidelines.

Faculty

Activity Chair
Leonard H. Calabrese, DO

Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Relevant Financial Disclosure:
Consultant: AbbVie, Bristol-Myers Squibb, Genentech, Gilead, GlaxoSmithKline, Lilly, Pfizer, Regeneron
Speaker Contracted by Ineligible Company: AbbVie, AstraZeneca, GlaxoSmithKline

Faculty
Phyllis C. Tien, MD

Associate Professor of Medicine
University of California, San Francisco
San Francisco VA Medical Center, Infectious Disease Section
San Francisco, CA

Relevant Financial Disclosure:
Independent Research Contractor (paid to institution): Gilead, Lilly, Merck

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Internal Medicine Presentations

0.25 CME
AGA Institute
Getting it Right in Ulcerative Colitis: A Clinical Guideline and Decision Tool-Based Approach

Getting it Right in Ulcerative Colitis: A Clinical Guideline and Decision Tool-Based Approach

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: April 22, 2022
Expires: April 21, 2023
15 minutes to complete

Provided By

This activity is provided by AGA. Produced in collaboration with RMEI Medical Education, LLC.

Target Audience

Gastroenterologists and primary care clinicians involved in the care of patients with inflammatory bowel disease (IBD).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Employ standards of care for the management of inflammatory bowel disease (IBD) as presented in current guidelines
  • Apply IBD clinical decision support tools to risk stratify patients and aid in therapeutic selection
  • Select IBD therapies based on risk stratification and guideline recommendations

Activity Description

Ulcerative colitis as a disease can vary widely between patients in its course, complication risk, and treatment, making risk stratification an important component of care. However, traditional high-risk indicators are falling out of favor as more evidence-based, patient-specific tools are being developed. In this self-paced, interactive, infographic with video commentary, tool demonstrations, and case-based learning, participants will learn more about these tools and AGA guidelines and care pathway for assessing and treating patients with ulcerative colitis.

Faculty

Parambir S. Dulai, MD
Associate Professor, Medicine
Director, GI Clinical Trials
Director, Precision Medicine
Division of Gastroenterology & Hepatology
Feinberg School of Medicine, Northwestern University
Evanston, IL


Dana Lukin, MD, PhD
Associate Professor, Clinical Medicine
Clinical Director, Translational Research
Jill Roberts Center for Inflammatory Bowel Disease
New York Presbyterian Hospital
Weill Cornell Medicine
New York, NY

Disclosure of Financial Relationships

In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 24 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Parambir S. Dulai, MD, has affiliations with Gilead, Janssen, Lilly, Pfizer, Takeda (Consulting Fee); DigbiHealth (Ownership Interest [Stocks]); PreciDiag (Royalty).

Dana Lukin, MD, PhD, has affiliations with AbbVie, BMS, Boehringer Ingelheim, Janssen, Palatin Technologies, Pfizer (Consulting Fee).

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

RMEI Medical Education, LLC
Sharon Powell, Senior Medical Editor, has no financial relationships to disclose.
Lobna Eldasher, PharmD, Medical Director, has no financial relationships to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

AGA Institute Reviewers
Alana Persaud, MD, has no financial relationships to disclose.
Faruq Pradhan, MD, FRCPC, has no financial relationships to disclose.
Richard Wu, MD, MPH, has affiliations with Medtronic (Education Grant, In Kind Support).
Kenneth W. Hung, MD, MS, has no financial relationships to disclose.
Naemat Sandhu, MD, has no financial relationships to disclose.

Accreditation Statement

The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The AGA Institute designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

Instructions for Receiving Credit

Fee Information
There is no fee for this educational activity.

Criteria for Success
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact AGA Institute at education@gastro.org.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

Your Feedback is Important! 

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC. 
No supporter funding was used for the expense of this gift card. 

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by educational grants from Takeda Pharmaceuticals, U.S.A., Inc., Ferring Pharmaceuticals, Inc., and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AGA Institute and RMEI Medical Education, LLC specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant’s misunderstanding of the content.

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: April 22, 2022
Expires: April 21, 2023
15 minutes to complete

Provided By

This activity is provided by AGA. Produced in collaboration with RMEI Medical Education, LLC.

Target Audience

Gastroenterologists and primary care clinicians involved in the care of patients with inflammatory bowel disease (IBD).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Employ standards of care for the management of inflammatory bowel disease (IBD) as presented in current guidelines
  • Apply IBD clinical decision support tools to risk stratify patients and aid in therapeutic selection
  • Select IBD therapies based on risk stratification and guideline recommendations

Activity Description

Ulcerative colitis as a disease can vary widely between patients in its course, complication risk, and treatment, making risk stratification an important component of care. However, traditional high-risk indicators are falling out of favor as more evidence-based, patient-specific tools are being developed. In this self-paced, interactive, infographic with video commentary, tool demonstrations, and case-based learning, participants will learn more about these tools and AGA guidelines and care pathway for assessing and treating patients with ulcerative colitis.

Faculty

Parambir S. Dulai, MD
Associate Professor, Medicine
Director, GI Clinical Trials
Director, Precision Medicine
Division of Gastroenterology & Hepatology
Feinberg School of Medicine, Northwestern University
Evanston, IL


Dana Lukin, MD, PhD
Associate Professor, Clinical Medicine
Clinical Director, Translational Research
Jill Roberts Center for Inflammatory Bowel Disease
New York Presbyterian Hospital
Weill Cornell Medicine
New York, NY

Disclosure of Financial Relationships

In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 24 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Parambir S. Dulai, MD, has affiliations with Gilead, Janssen, Lilly, Pfizer, Takeda (Consulting Fee); DigbiHealth (Ownership Interest [Stocks]); PreciDiag (Royalty).

Dana Lukin, MD, PhD, has affiliations with AbbVie, BMS, Boehringer Ingelheim, Janssen, Palatin Technologies, Pfizer (Consulting Fee).

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

RMEI Medical Education, LLC
Sharon Powell, Senior Medical Editor, has no financial relationships to disclose.
Lobna Eldasher, PharmD, Medical Director, has no financial relationships to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

AGA Institute Reviewers
Alana Persaud, MD, has no financial relationships to disclose.
Faruq Pradhan, MD, FRCPC, has no financial relationships to disclose.
Richard Wu, MD, MPH, has affiliations with Medtronic (Education Grant, In Kind Support).
Kenneth W. Hung, MD, MS, has no financial relationships to disclose.
Naemat Sandhu, MD, has no financial relationships to disclose.

Accreditation Statement

The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The AGA Institute designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

Instructions for Receiving Credit

Fee Information
There is no fee for this educational activity.

Criteria for Success
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact AGA Institute at education@gastro.org.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

Your Feedback is Important! 

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC. 
No supporter funding was used for the expense of this gift card. 

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by educational grants from Takeda Pharmaceuticals, U.S.A., Inc., Ferring Pharmaceuticals, Inc., and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AGA Institute and RMEI Medical Education, LLC specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant’s misunderstanding of the content.

0.25 CME
AGA Institute
Getting it Right in Crohn’s Disease: A Clinical Guideline and Decision Tool-Based Approach

Getting it Right in Crohn’s Disease: A Clinical Guideline and Decision Tool-Based Approach

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: April 22, 2022
Expires: April 21, 2023
15 minutes to complete

Provided By

This activity is provided by AGA. Produced in collaboration with RMEI Medical Education, LLC.

Target Audience

Gastroenterologists and primary care clinicians involved in the care of patients with inflammatory bowel disease (IBD).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Employ standards of care for the management of inflammatory bowel disease (IBD) as presented in current guidelines
  • Apply IBD clinical decision support tools to risk stratify patients and aid in therapeutic selection
  • Select IBD therapies based on risk stratification and guideline recommendations

Activity Description

Despite evidence supporting usefulness of patient-specific risk stratification and personalized treatment, many patients with Crohn’s disease continue to be undertreated. In this activity, learners will explore new and available tools to help risk stratify patients with Crohn’s disease, predict the likelihood of response to various biologic therapies, and select appropriate treatment using these tools and AGA guidelines and care pathways. This activity provides tool demonstrations, video commentary, and case presentations all in one interactive, self-paced infographic.

Faculty

Parambir S. Dulai, MD
Associate Professor, Medicine
Director, GI Clinical Trials
Director, Precision Medicine
Division of Gastroenterology & Hepatology
Feinberg School of Medicine, Northwestern University
Evanston, IL


Corey A. Siegel, MD, MS
Professor of Medicine and of The Dartmouth Institute for Health Policy and Clinical Practice
Geisel School of Medicine at Dartmouth
Section Chief, Gastroenterology and Hepatology
Co-Director, IBD Center
Dartmouth-Hitchcock Medical Center
Hanover, NH

Disclosure of Financial Relationships

In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 24 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Parambir S. Dulai, MD, has affiliations with Gilead, Janssen, Lilly, Pfizer, Takeda (Consulting Fee); DigbiHealth (Ownership Interest [Stocks]); PreciDiag (Royalty).

Corey A. Siegel, MD, MS, has affiliations with AbbVie, BMS, Janssen, Lilly, Napo Pharmaceuticals, Pfizer, Prometheus Biosciences, Takeda, Trellus Health (Consulting Fee); AbbVie, Pfizer, Takeda (Grant/Research Support); Takeda (Speaker/Teacher); MiTest Health (Royalty).

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

RMEI Medical Education, LLC
Sharon Powell, Senior Medical Editor, has no financial relationships to disclose.
Lobna Eldasher, PharmD, Medical Director, has no financial relationships to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

AGA Institute Reviewers
Alana Persaud, MD, has no financial relationships to disclose.
Faruq Pradhan, MD, FRCPC, has no financial relationships to disclose.
Richard Wu, MD, MPH, has affiliations with Medtronic (Education Grant, In Kind Support).
Kenneth W. Hung, MD, MS, has no financial relationships to disclose.
Naemat Sandhu, MD, has no financial relationships to disclose.

Accreditation Statement

The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The AGA Institute designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

Instructions for Receiving Credit

Fee Information
There is no fee for this educational activity.

Criteria for Success
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact AGA Institute at education@gastro.org.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

Your Feedback is Important! 

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC. 
No supporter funding was used for the expense of this gift card. 

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by educational grants from Takeda Pharmaceuticals, U.S.A., Inc., Ferring Pharmaceuticals, Inc., and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AGA Institute and RMEI Medical Education, LLC specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant’s misunderstanding of the content.

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: April 22, 2022
Expires: April 21, 2023
15 minutes to complete

Provided By

This activity is provided by AGA. Produced in collaboration with RMEI Medical Education, LLC.

Target Audience

Gastroenterologists and primary care clinicians involved in the care of patients with inflammatory bowel disease (IBD).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Employ standards of care for the management of inflammatory bowel disease (IBD) as presented in current guidelines
  • Apply IBD clinical decision support tools to risk stratify patients and aid in therapeutic selection
  • Select IBD therapies based on risk stratification and guideline recommendations

Activity Description

Despite evidence supporting usefulness of patient-specific risk stratification and personalized treatment, many patients with Crohn’s disease continue to be undertreated. In this activity, learners will explore new and available tools to help risk stratify patients with Crohn’s disease, predict the likelihood of response to various biologic therapies, and select appropriate treatment using these tools and AGA guidelines and care pathways. This activity provides tool demonstrations, video commentary, and case presentations all in one interactive, self-paced infographic.

Faculty

Parambir S. Dulai, MD
Associate Professor, Medicine
Director, GI Clinical Trials
Director, Precision Medicine
Division of Gastroenterology & Hepatology
Feinberg School of Medicine, Northwestern University
Evanston, IL


Corey A. Siegel, MD, MS
Professor of Medicine and of The Dartmouth Institute for Health Policy and Clinical Practice
Geisel School of Medicine at Dartmouth
Section Chief, Gastroenterology and Hepatology
Co-Director, IBD Center
Dartmouth-Hitchcock Medical Center
Hanover, NH

Disclosure of Financial Relationships

In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 24 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Parambir S. Dulai, MD, has affiliations with Gilead, Janssen, Lilly, Pfizer, Takeda (Consulting Fee); DigbiHealth (Ownership Interest [Stocks]); PreciDiag (Royalty).

Corey A. Siegel, MD, MS, has affiliations with AbbVie, BMS, Janssen, Lilly, Napo Pharmaceuticals, Pfizer, Prometheus Biosciences, Takeda, Trellus Health (Consulting Fee); AbbVie, Pfizer, Takeda (Grant/Research Support); Takeda (Speaker/Teacher); MiTest Health (Royalty).

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

RMEI Medical Education, LLC
Sharon Powell, Senior Medical Editor, has no financial relationships to disclose.
Lobna Eldasher, PharmD, Medical Director, has no financial relationships to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

AGA Institute Reviewers
Alana Persaud, MD, has no financial relationships to disclose.
Faruq Pradhan, MD, FRCPC, has no financial relationships to disclose.
Richard Wu, MD, MPH, has affiliations with Medtronic (Education Grant, In Kind Support).
Kenneth W. Hung, MD, MS, has no financial relationships to disclose.
Naemat Sandhu, MD, has no financial relationships to disclose.

Accreditation Statement

The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The AGA Institute designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

Instructions for Receiving Credit

Fee Information
There is no fee for this educational activity.

Criteria for Success
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact AGA Institute at education@gastro.org.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

Your Feedback is Important! 

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC. 
No supporter funding was used for the expense of this gift card. 

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by educational grants from Takeda Pharmaceuticals, U.S.A., Inc., Ferring Pharmaceuticals, Inc., and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AGA Institute and RMEI Medical Education, LLC specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant’s misunderstanding of the content.

Marwan Noel Sabbagh, MD, FAAN
0.5 AAFP / CME
RMEI Medical Education, LLC
The Increasingly Vital Role of Early Alzheimer’s Disease Diagnosis & Treatment in Averting the Amyloid Tipping Point

The Increasingly Vital Role of Early Alzheimer’s Disease Diagnosis & Treatment in Averting the Amyloid Tipping Point

Start

Activity Details

Free CME/AAFP
0.5 AMA PRA Category 1 Credit(s)
0.5 AAFP Prescribed Credit(s)
Released: April 15, 2022
Expires: April 14, 2023
30 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for neurology and primary care clinicians (MD/DO/NP/PA) engaged in the care of patients with Alzheimer’s disease.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify mild cognitive impairment and early Alzheimer’s disease with the help of screening tools, biomarkers, and neuroimaging techniques
  • Integrate approved and emerging anti-amyloid β therapies for the treatment of mild cognitive impairment and early-stage Alzheimer’s disease

Activity Description

Alzheimer’s disease (AD) is a growing public health concern, and as the aging population rapidly increases, so too does the number of individuals affected by AD. The recent availability of therapy for mild cognitive impairment (MCI) and early-stage AD has increased the need for early screening. In this uniquely designed, reflective activity, learners are presented with 2 cases related to AD and challenged to think about how the patients could have been better assessed/managed. A multidisciplinary discussion between a primary care physician (PCP) and neurologist will combine elements of cognitive assessment, proper screening and referral, and early management to demonstrate the critical relationship PCPs and neurologists have in identifying and managing patients with MCI/early-stage AD.

Chair

Marwan Noel Sabbagh, MD, FAAN
Professor, Neurology
Barrow Neurological Institute
Phoenix, AZ

Faculty

Warren A. Jones, MD, FAAFP
Professor Emeritus, University of Mississippi Medical Center
Chief Health Officer, The Jones Group of Mississippi
Jackson, MS

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Warren A. Jones, MD, FAAFP, has no relevant financial relationship(s) with ineligible companies to disclose.

Marwan Noel Sabbagh, MD, FAAN, has relevant financial relationships with Acadia Pharmaceuticals, Alzheon, Biogen, Cortexyme, Eisai, Eli Lilly, Genentech, KeifeRx, Qynapse, Renew Research, T3D Therapeutics (Consultant); Athira, Brain Health Inc., Cognoptix, NeuroTau, Optimal Cognitive Health Company, TransDermix, uMethod Health, Versanum (Stock/Shareholder); Clinical Options, Health and Wellness Partners (Speaker/Speaker’s Bureau); Humanix (Other: Royalties).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAFP Prescribed Credits
The AAFP has reviewed The Increasingly Vital Role of Early Alzheimer’s Disease Diagnosis & Treatment in Averting the Amyloid Tipping Point and deemed it acceptable for up to 0.50 Enduring Materials, Self-Study AAFP Prescribed credits. Term of Approval is from 04/15/2022 to 04/14/2023. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 Credit(s)™ toward the AMA Physician’s Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent educational grant from Biogen MA, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/AAFP
0.5 AMA PRA Category 1 Credit(s)
0.5 AAFP Prescribed Credit(s)
Released: April 15, 2022
Expires: April 14, 2023
30 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for neurology and primary care clinicians (MD/DO/NP/PA) engaged in the care of patients with Alzheimer’s disease.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify mild cognitive impairment and early Alzheimer’s disease with the help of screening tools, biomarkers, and neuroimaging techniques
  • Integrate approved and emerging anti-amyloid β therapies for the treatment of mild cognitive impairment and early-stage Alzheimer’s disease

Activity Description

Alzheimer’s disease (AD) is a growing public health concern, and as the aging population rapidly increases, so too does the number of individuals affected by AD. The recent availability of therapy for mild cognitive impairment (MCI) and early-stage AD has increased the need for early screening. In this uniquely designed, reflective activity, learners are presented with 2 cases related to AD and challenged to think about how the patients could have been better assessed/managed. A multidisciplinary discussion between a primary care physician (PCP) and neurologist will combine elements of cognitive assessment, proper screening and referral, and early management to demonstrate the critical relationship PCPs and neurologists have in identifying and managing patients with MCI/early-stage AD.

Chair

Marwan Noel Sabbagh, MD, FAAN
Professor, Neurology
Barrow Neurological Institute
Phoenix, AZ

Faculty

Warren A. Jones, MD, FAAFP
Professor Emeritus, University of Mississippi Medical Center
Chief Health Officer, The Jones Group of Mississippi
Jackson, MS

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Warren A. Jones, MD, FAAFP, has no relevant financial relationship(s) with ineligible companies to disclose.

Marwan Noel Sabbagh, MD, FAAN, has relevant financial relationships with Acadia Pharmaceuticals, Alzheon, Biogen, Cortexyme, Eisai, Eli Lilly, Genentech, KeifeRx, Qynapse, Renew Research, T3D Therapeutics (Consultant); Athira, Brain Health Inc., Cognoptix, NeuroTau, Optimal Cognitive Health Company, TransDermix, uMethod Health, Versanum (Stock/Shareholder); Clinical Options, Health and Wellness Partners (Speaker/Speaker’s Bureau); Humanix (Other: Royalties).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAFP Prescribed Credits
The AAFP has reviewed The Increasingly Vital Role of Early Alzheimer’s Disease Diagnosis & Treatment in Averting the Amyloid Tipping Point and deemed it acceptable for up to 0.50 Enduring Materials, Self-Study AAFP Prescribed credits. Term of Approval is from 04/15/2022 to 04/14/2023. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 Credit(s)™ toward the AMA Physician’s Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent educational grant from Biogen MA, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Sheetal Desai, MD, MSEd
0.75 AANP / AAPA / CME
Integrity Continuing Education, Inc.
A Light in the Darkness: Advances in Systemic Lupus Erythematosus

A Light in the Darkness: Advances in Systemic Lupus Erythematosus

Start

Activity Details

Free CME/AAPA/AANP
0.75 AMA PRA Category 1 Credit
0.75 Contact Hour(s)
Released: March 31, 2022
Expires: March 31, 2023
45 minutes to complete

Provider Statement

This CME activity for ACCME and AAPA credit is provided by Integrity Continuing Education, Inc.

This CE activity for AANP credit is jointly provided by Global Education Group and Integrity Continuing Education, Inc.

Target Audience

This educational activity has been designed to meet the needs of rheumatologists, nurse practitioners, and physician assistants involved in the management of patients with Systemic Lupus Erythematosus (SLE).

Learning Objectives

  • DEMONSTRATE how to apply current evidence to the effective management of SLE
  • DESCRIBE current and emerging clinical evaluation tools and rating instruments used in clinical trials and/or clinical practice for patients with SLE
  • DISCUSS the utility of patient-centered shared decision-making and patient-reported outcomes in improving adherence and quality of life in patients with SLE
  • REVIEW mechanisms of action and outcomes data from recent clinical trials on new and emerging SLE targeted therapies

Activity Description

Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disorder associated with significant morbidity and mortality, which impacts quality of life and life expectancy. Therapeutic strategies rely heavily on the use of corticosteroids to control inflammation; however, chronic use of these agents is responsible for much of the long-term damage accrual in SLE. Alongside corticosteroids, immunomodulators (hydroxychloroquine and vitamin D) should be maximized, and active disease should be controlled with immunosuppression or biologics when required. Due to the lack of standardized, objective clinical measures, rheumatology clinicians may delay escalation to an advanced therapy, causing many patients to linger unnecessarily on first-line therapies.

This activity will address evolving clinical evaluation tools and rating instruments that are necessary to fully understand clinical trial outcomes, integrate emerging treatments into clinical practice, and identify patients who would benefit most from these novel therapies.

Faculty

Sheetal Desai, MD, MSEd
Associate Professor
Department of Rheumatology
University of California, Irvine
Orange, California

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. and Global Education Group require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. and Global Education Group, for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CE/CME activities:

Sheetal Desai, MD, MSEd
Consulting: AstraZeneca, Aurinia Pharmaceuticals Inc., GlaxoSmithKline, Janssen Pharmaceuticals

Dave Mittman, DMSc (h.d.), PA, DFAAPA (Peer Reviewer) has no real or apparent conflicts of interest to report.

The following project managers/planners: Olivia Benevento, Stefani Chiarolanza, Lindsay Borvansky, Ashley Cann, Kristin Delisi, NP, Donna Fausak, Andrea Funk, Liddy Knight, and Patima Tanapat, PhD, reported that they or their spouses/life partners have no financial relationships or relationships to products or devices with commercial interests related to the content of this CE/CME activity.

Accreditation

Physician Continuing Education

Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
Integrity Continuing Education, Inc. designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integrity Continuing Education, Inc. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 0.75 contact hour(s) (which includes 0.2 hour(s) of pharmacology).

Physician Assistant Continuing Education (AAPA)
This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid from 3/31/2022 to 3/31/2023. PAs should only claim credit commensurate with the extent of their participation. AAPA reference number: CME-204547.

Instructions for Receiving Credit

There are no fees for participating and receiving CE/CME credit for this activity. During the period of March, 31, 2022 through March, 31, 2023, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Successful completion of the posttest is required to earn AAPA Category 1 CME credit. Successful completion is defined as a cumulative score of at least 70 percent correct.

Statement of Commercial Support

This activity is supported by an education grant from AstraZeneca Pharmaceuticals.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Global Education Group, do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions About the Activity

For information about ACCME or AAPA accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

For information about AANP accreditation of this activity, please contact Global Education Group at (303) 395-1782 or cme@globaleducationgroup.com.

Activity Details

Free CME/AAPA/AANP
0.75 AMA PRA Category 1 Credit
0.75 Contact Hour(s)
Released: March 31, 2022
Expires: March 31, 2023
45 minutes to complete

Provider Statement

This CME activity for ACCME and AAPA credit is provided by Integrity Continuing Education, Inc.

This CE activity for AANP credit is jointly provided by Global Education Group and Integrity Continuing Education, Inc.

Target Audience

This educational activity has been designed to meet the needs of rheumatologists, nurse practitioners, and physician assistants involved in the management of patients with Systemic Lupus Erythematosus (SLE).

Learning Objectives

  • DEMONSTRATE how to apply current evidence to the effective management of SLE
  • DESCRIBE current and emerging clinical evaluation tools and rating instruments used in clinical trials and/or clinical practice for patients with SLE
  • DISCUSS the utility of patient-centered shared decision-making and patient-reported outcomes in improving adherence and quality of life in patients with SLE
  • REVIEW mechanisms of action and outcomes data from recent clinical trials on new and emerging SLE targeted therapies

Activity Description

Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disorder associated with significant morbidity and mortality, which impacts quality of life and life expectancy. Therapeutic strategies rely heavily on the use of corticosteroids to control inflammation; however, chronic use of these agents is responsible for much of the long-term damage accrual in SLE. Alongside corticosteroids, immunomodulators (hydroxychloroquine and vitamin D) should be maximized, and active disease should be controlled with immunosuppression or biologics when required. Due to the lack of standardized, objective clinical measures, rheumatology clinicians may delay escalation to an advanced therapy, causing many patients to linger unnecessarily on first-line therapies.

This activity will address evolving clinical evaluation tools and rating instruments that are necessary to fully understand clinical trial outcomes, integrate emerging treatments into clinical practice, and identify patients who would benefit most from these novel therapies.

Faculty

Sheetal Desai, MD, MSEd
Associate Professor
Department of Rheumatology
University of California, Irvine
Orange, California

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. and Global Education Group require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. and Global Education Group, for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CE/CME activities:

Sheetal Desai, MD, MSEd
Consulting: AstraZeneca, Aurinia Pharmaceuticals Inc., GlaxoSmithKline, Janssen Pharmaceuticals

Dave Mittman, DMSc (h.d.), PA, DFAAPA (Peer Reviewer) has no real or apparent conflicts of interest to report.

The following project managers/planners: Olivia Benevento, Stefani Chiarolanza, Lindsay Borvansky, Ashley Cann, Kristin Delisi, NP, Donna Fausak, Andrea Funk, Liddy Knight, and Patima Tanapat, PhD, reported that they or their spouses/life partners have no financial relationships or relationships to products or devices with commercial interests related to the content of this CE/CME activity.

Accreditation

Physician Continuing Education

Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
Integrity Continuing Education, Inc. designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integrity Continuing Education, Inc. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 0.75 contact hour(s) (which includes 0.2 hour(s) of pharmacology).

Physician Assistant Continuing Education (AAPA)
This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid from 3/31/2022 to 3/31/2023. PAs should only claim credit commensurate with the extent of their participation. AAPA reference number: CME-204547.

Instructions for Receiving Credit

There are no fees for participating and receiving CE/CME credit for this activity. During the period of March, 31, 2022 through March, 31, 2023, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Successful completion of the posttest is required to earn AAPA Category 1 CME credit. Successful completion is defined as a cumulative score of at least 70 percent correct.

Statement of Commercial Support

This activity is supported by an education grant from AstraZeneca Pharmaceuticals.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Global Education Group, do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions About the Activity

For information about ACCME or AAPA accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

For information about AANP accreditation of this activity, please contact Global Education Group at (303) 395-1782 or cme@globaleducationgroup.com.

Leonard H. Calabrese, DO
0.25 CME
Vindico Medical Education
Case Conundrums in COVID-19: Primer on the Immune Basis of COVID-19 Progression

Case Conundrums in COVID-19: Primer on the Immune Basis of COVID-19 Progression

Start
Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: March 30, 2022
Expires: March 29, 2023
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is rheumatologists, hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, and other health care professionals involved in the management of patients hospitalized with COVID-19.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Describe the role of the innate and adaptive immune response underlying the progression of COVID-19 from early-stage disease to hospitalization to hyperinflammation.

Activity Description

In this 4-part Curbside Consults video series, experts from infectious disease, pulmonology, and rheumatology will review clinical cases across the spectrum of COVID-19 disease. Strategies will be discussed for the prevention and management of severe COVID-19–associated hyperinflammation and respiratory damage.

Statement of Educational Need

The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Targeted immunomodulatory treatments can reduce the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up to date on the latest evidence-based care and rapidly evolving treatment guidelines.

Faculty

Activity Chair
Leonard H. Calabrese, DO

Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Relevant Financial Disclosure:
Consultant: AbbVie, Bristol-Myers Squibb, Genentech, Gilead, GlaxoSmithKline, Lilly, Pfizer, Regeneron
Speaker Contracted by Ineligible Company: AbbVie, AstraZeneca, GlaxoSmithKline

Faculty
Randy Q. Cron, MD, PhD

Professor of Pediatrics
Arthritis Foundation, Alabama Chapter Endowed Chair in Pediatric Rheumatology
University of Alabama at Birmingham Heersink School of Medicine
Birmingham, AL

Relevant Financial Disclosure:
Advisor: Sobi
Consultant: Sironax, Sobi
Speaker Contracted by Ineligible Company: Sobi
Independent Research Contractor: Sobi
Adjudication Committee Chair: Pfizer

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: March 30, 2022
Expires: March 29, 2023
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is rheumatologists, hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, and other health care professionals involved in the management of patients hospitalized with COVID-19.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Describe the role of the innate and adaptive immune response underlying the progression of COVID-19 from early-stage disease to hospitalization to hyperinflammation.

Activity Description

In this 4-part Curbside Consults video series, experts from infectious disease, pulmonology, and rheumatology will review clinical cases across the spectrum of COVID-19 disease. Strategies will be discussed for the prevention and management of severe COVID-19–associated hyperinflammation and respiratory damage.

Statement of Educational Need

The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Targeted immunomodulatory treatments can reduce the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up to date on the latest evidence-based care and rapidly evolving treatment guidelines.

Faculty

Activity Chair
Leonard H. Calabrese, DO

Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Relevant Financial Disclosure:
Consultant: AbbVie, Bristol-Myers Squibb, Genentech, Gilead, GlaxoSmithKline, Lilly, Pfizer, Regeneron
Speaker Contracted by Ineligible Company: AbbVie, AstraZeneca, GlaxoSmithKline

Faculty
Randy Q. Cron, MD, PhD

Professor of Pediatrics
Arthritis Foundation, Alabama Chapter Endowed Chair in Pediatric Rheumatology
University of Alabama at Birmingham Heersink School of Medicine
Birmingham, AL

Relevant Financial Disclosure:
Advisor: Sobi
Consultant: Sironax, Sobi
Speaker Contracted by Ineligible Company: Sobi
Independent Research Contractor: Sobi
Adjudication Committee Chair: Pfizer

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Leonard H. Calabrese, DO
0.25 CME
Vindico Medical Education
Case Conundrums in COVID-19: A Patient Presenting to the ED With Mild COVID-19

Case Conundrums in COVID-19: A Patient Presenting to the ED With Mild COVID-19

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: March 30, 2022
Expires: March 29, 2023
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is rheumatologists, hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, and other health care professionals involved in the management of patients hospitalized with COVID-19.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Evaluate the latest data regarding immune-based therapies, including glucocorticoids, JAK inhibitors, and other targeted therapies for the management of patients with COVID-19.
  • Recognize how variables such as disease severity, comorbidities, and immunologic endotypes may impact the management of patients with COVID-19.

Activity Description

In this 4-part Curbside Consults video series, experts from infectious disease, pulmonology, and rheumatology will review clinical cases across the spectrum of COVID-19 disease. Strategies will be discussed for the prevention and management of severe COVID-19–associated hyperinflammation and respiratory damage.

Statement of Educational Need

The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Targeted immunomodulatory treatments can reduce the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up to date on the latest evidence-based care and rapidly evolving treatment guidelines.

Faculty

Activity Chair
Leonard H. Calabrese, DO

Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Relevant Financial Disclosure:
Consultant: AbbVie, Bristol-Myers Squibb, Genentech, Gilead, GlaxoSmithKline, Lilly, Pfizer, Regeneron
Speaker Contracted by Ineligible Company: AbbVie, AstraZeneca, GlaxoSmithKline

Faculty
Phyllis C. Tien, MD

Associate Professor of Medicine
University of California, San Francisco
San Francisco VA Medical Center, Infectious Disease Section
San Francisco, CA

Relevant Financial Disclosure:
Independent Research Contractor (paid to institution): Gilead, Lilly, Merck

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: March 30, 2022
Expires: March 29, 2023
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is rheumatologists, hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, and other health care professionals involved in the management of patients hospitalized with COVID-19.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Evaluate the latest data regarding immune-based therapies, including glucocorticoids, JAK inhibitors, and other targeted therapies for the management of patients with COVID-19.
  • Recognize how variables such as disease severity, comorbidities, and immunologic endotypes may impact the management of patients with COVID-19.

Activity Description

In this 4-part Curbside Consults video series, experts from infectious disease, pulmonology, and rheumatology will review clinical cases across the spectrum of COVID-19 disease. Strategies will be discussed for the prevention and management of severe COVID-19–associated hyperinflammation and respiratory damage.

Statement of Educational Need

The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Targeted immunomodulatory treatments can reduce the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up to date on the latest evidence-based care and rapidly evolving treatment guidelines.

Faculty

Activity Chair
Leonard H. Calabrese, DO

Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Relevant Financial Disclosure:
Consultant: AbbVie, Bristol-Myers Squibb, Genentech, Gilead, GlaxoSmithKline, Lilly, Pfizer, Regeneron
Speaker Contracted by Ineligible Company: AbbVie, AstraZeneca, GlaxoSmithKline

Faculty
Phyllis C. Tien, MD

Associate Professor of Medicine
University of California, San Francisco
San Francisco VA Medical Center, Infectious Disease Section
San Francisco, CA

Relevant Financial Disclosure:
Independent Research Contractor (paid to institution): Gilead, Lilly, Merck

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Leonard H. Calabrese, DO
0.25 CME
Vindico Medical Education
Case Conundrums in COVID-19: A Newly Admitted Patient With COVID-19 and Worsening Respiratory Symptoms

Case Conundrums in COVID-19: A Newly Admitted Patient With COVID-19 and Worsening Respiratory Symptoms

Start
Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: March 30, 2022
Expires: March 29, 2023
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is rheumatologists, hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, and other health care professionals involved in the management of patients hospitalized with COVID-19.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Evaluate the latest data regarding immune-based therapies, including glucocorticoids, JAK inhibitors, and other targeted therapies for the management of patients with COVID-19.
  • Recognize how variables such as disease severity, comorbidities, and immunologic endotypes may impact the management of patients with COVID-19.

Activity Description

In this 4-part Curbside Consults video series, experts from infectious disease, pulmonology, and rheumatology will review clinical cases across the spectrum of COVID-19 disease. Strategies will be discussed for the prevention and management of severe COVID-19–associated hyperinflammation and respiratory damage.

Statement of Educational Need

The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Targeted immunomodulatory treatments can reduce the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up to date on the latest evidence-based care and rapidly evolving treatment guidelines.

Faculty

Activity Chair
Leonard H. Calabrese, DO

Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Relevant Financial Disclosure:
Consultant: AbbVie, Bristol-Myers Squibb, Genentech, Gilead, GlaxoSmithKline, Lilly, Pfizer, Regeneron
Speaker Contracted by Ineligible Company: AbbVie, AstraZeneca, GlaxoSmithKline

Faculty
Phyllis C. Tien, MD

Associate Professor of Medicine
University of California, San Francisco
San Francisco VA Medical Center, Infectious Disease Section
San Francisco, CA

Relevant Financial Disclosure:
Independent Research Contractor (paid to institution): Gilead, Lilly, Merck

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: March 30, 2022
Expires: March 29, 2023
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is rheumatologists, hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, and other health care professionals involved in the management of patients hospitalized with COVID-19.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Evaluate the latest data regarding immune-based therapies, including glucocorticoids, JAK inhibitors, and other targeted therapies for the management of patients with COVID-19.
  • Recognize how variables such as disease severity, comorbidities, and immunologic endotypes may impact the management of patients with COVID-19.

Activity Description

In this 4-part Curbside Consults video series, experts from infectious disease, pulmonology, and rheumatology will review clinical cases across the spectrum of COVID-19 disease. Strategies will be discussed for the prevention and management of severe COVID-19–associated hyperinflammation and respiratory damage.

Statement of Educational Need

The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Targeted immunomodulatory treatments can reduce the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up to date on the latest evidence-based care and rapidly evolving treatment guidelines.

Faculty

Activity Chair
Leonard H. Calabrese, DO

Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Relevant Financial Disclosure:
Consultant: AbbVie, Bristol-Myers Squibb, Genentech, Gilead, GlaxoSmithKline, Lilly, Pfizer, Regeneron
Speaker Contracted by Ineligible Company: AbbVie, AstraZeneca, GlaxoSmithKline

Faculty
Phyllis C. Tien, MD

Associate Professor of Medicine
University of California, San Francisco
San Francisco VA Medical Center, Infectious Disease Section
San Francisco, CA

Relevant Financial Disclosure:
Independent Research Contractor (paid to institution): Gilead, Lilly, Merck

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Leonard H. Calabrese, DO
0.25 CME
Vindico Medical Education
Case Conundrums in COVID-19: A Patient With COVID-19 Experiencing Hyperinflammation

Case Conundrums in COVID-19: A Patient With COVID-19 Experiencing Hyperinflammation

Start
Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: March 30, 2022
Expires: March 29, 2023
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is rheumatologists, hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, and other health care professionals involved in the management of patients hospitalized with COVID-19.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Evaluate the latest data regarding immune-based therapies, including glucocorticoids, JAK inhibitors, and other targeted therapies for the management of patients with COVID-19.
  • Recognize how variables such as disease severity, comorbidities, and immunologic endotypes may impact the management of patients with COVID-19.

Activity Description

In this 4-part Curbside Consults video series, experts from infectious disease, pulmonology, and rheumatology will review clinical cases across the spectrum of COVID-19 disease. Strategies will be discussed for the prevention and management of severe COVID-19–associated hyperinflammation and respiratory damage.

Statement of Educational Need

The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Targeted immunomodulatory treatments can reduce the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up to date on the latest evidence-based care and rapidly evolving treatment guidelines.

Faculty

Activity Chair
Leonard H. Calabrese, DO

Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Relevant Financial Disclosure:
Consultant: AbbVie, Bristol-Myers Squibb, Genentech, Gilead, GlaxoSmithKline, Lilly, Pfizer, Regeneron
Speaker Contracted by Ineligible Company: AbbVie, AstraZeneca, GlaxoSmithKline

Faculty
Randy Q. Cron, MD, PhD

Professor of Pediatrics
Arthritis Foundation, Alabama Chapter Endowed Chair in Pediatric Rheumatology
University of Alabama at Birmingham Heersink School of Medicine
Birmingham, AL

Relevant Financial Disclosure:
Advisor: Sobi
Consultant: Sironax, Sobi
Speaker Contracted by Ineligible Company: Sobi
Independent Research Contractor: Sobi
Adjudication Committee Chair: Pfizer

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: March 30, 2022
Expires: March 29, 2023
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is rheumatologists, hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, and other health care professionals involved in the management of patients hospitalized with COVID-19.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Evaluate the latest data regarding immune-based therapies, including glucocorticoids, JAK inhibitors, and other targeted therapies for the management of patients with COVID-19.
  • Recognize how variables such as disease severity, comorbidities, and immunologic endotypes may impact the management of patients with COVID-19.

Activity Description

In this 4-part Curbside Consults video series, experts from infectious disease, pulmonology, and rheumatology will review clinical cases across the spectrum of COVID-19 disease. Strategies will be discussed for the prevention and management of severe COVID-19–associated hyperinflammation and respiratory damage.

Statement of Educational Need

The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Targeted immunomodulatory treatments can reduce the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up to date on the latest evidence-based care and rapidly evolving treatment guidelines.

Faculty

Activity Chair
Leonard H. Calabrese, DO

Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Relevant Financial Disclosure:
Consultant: AbbVie, Bristol-Myers Squibb, Genentech, Gilead, GlaxoSmithKline, Lilly, Pfizer, Regeneron
Speaker Contracted by Ineligible Company: AbbVie, AstraZeneca, GlaxoSmithKline

Faculty
Randy Q. Cron, MD, PhD

Professor of Pediatrics
Arthritis Foundation, Alabama Chapter Endowed Chair in Pediatric Rheumatology
University of Alabama at Birmingham Heersink School of Medicine
Birmingham, AL

Relevant Financial Disclosure:
Advisor: Sobi
Consultant: Sironax, Sobi
Speaker Contracted by Ineligible Company: Sobi
Independent Research Contractor: Sobi
Adjudication Committee Chair: Pfizer

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

David A. Wohl, MD
1.0 CME / MOC / CPE
Vindico Medical Education
HIV PrEP: Strategies for Risk Reduction and Improved Adherence

HIV PrEP: Strategies for Risk Reduction and Improved Adherence

Start

Activity Details

Free CME/MOC/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 ABIM MOC Point(s)
1.0 ACPE Contact Hour(s)
Released: March 15, 2022
Expires: March 14, 2023
60 minutes to complete

Accredited By

This continuing education activity is provided by

Target Audience

The intended audience for the activity is family medicine physicians, internists, pharmacists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients at high risk for acquiring HIV.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Evaluate complications of untreated HIV as well as the tools for risk assessments and routine screening.
  • Identify patient eligibility and the categories of patients who may benefit from pre-exposure prophylaxis (PrEP).
  • Review the latest clinical evidence regarding current and emerging PrEP therapies, including guidance on medication adherence and risk-reduction counseling.

Activity Description

HIV is a disease that attacks the body’s immune system. Patients with HIV have the capability to transmit the virus to other patients via either sex or sharing of needles or syringes. If HIV is not treated, it can lead to AIDS, which is the most severe phase of HIV infection. Because there is no effective vaccine to prevent HIV transmission, behavioral and biomedical HIV prevention strategies are needed to reduce HIV acquisition. For HIV-uninfected patients, PrEP using antiretroviral medications is an evidence-based method to prevent new infections among those at greatest risk, as data have shown that it is highly effective in individuals who are adherent to taking the PrEP agent. In this CE activity, the faculty for this program will identify the categories of patients who may benefit from PrEP, as well as explore the safety and efficacy of current PrEP therapies, and will utilize the unique ArcheMedX Intelligent Learning Platform.

Statement of Educational Need

Several quality care gaps exist when managing individuals who are at high risk for developing HIV. This insufficient care is attributed to numerous factors, including primary care physicians and other providers who do not perform routine screenings and risk assessments of patients, do not discuss PrEP or any other risk prevention strategies with patients who may exhibit high-risk behaviors, do not actively promote adherence to PrEP or follow up with patients, and who lack competence about current PrEP therapies. As such, an educational initiative discussing these topics is warranted to improve outcomes for patients who are at high risk for acquiring HIV.

Agenda

Introduction - David A. Wohl, MD

Burden of HIV and Tools for Risk Assessment - Latesha Elopre, MD, MSPH

PrEP Therapies and Adherence Strategies - David A. Wohl, MD

Case Presentation & Panel Discussion - All Faculty

Activity Chair

David A. Wohl, MD
Professor of Medicine
Division of Infectious Diseases
University of North Carolina at Chapel Hill School of Medicine
Chapel Hill, NC

Disclosure:
Advisor: Gilead, Merck, ViiV
Consultant: Gilead, Merck, ViiV
Independent Research Contractor: Gilead, Merck, ViiV

Faculty

Latesha Elopre, MD, MSPH
Associate Professor
Division of Infectious Diseases
University of Alabama at Birmingham
Birmingham, AL

Disclosure: No relevant financial relationships to disclose.

Planners/Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Jennifer Cocohoba, PharmD, MAS, BCPS, AAHIVP
Disclosure:
Independent Research Contractor: Actelion/Janssen, ViiV

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Accreditation Council for Pharmacy EducationVindico Medical Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Successful completion of this CME activity enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in by providing their ABIM ID and DOB (MM/DD) will earn MOC points equivalent to the amount of CME credits claimed for the activity.

This program is acceptable for 1.0 contact hour of ACPE Continuing Education Credit. The ACPE Universal Program Number 0482-0000-22-002-H02-P, effective 03/15/2022. This is a knowledge-based activity, and there is no fee to attend.

Vindico Medical Education will provide pharmacist credits claimed information directly to the ACPE through CPE Monitor within 45 days.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.

Physician assistants participating in the activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

This enduring material is approved for 1 year from the date of original release, March 15, 2022 to March 14, 2023.

Instructions for Receiving Credit

To participate in this CE activity, you must read the objectives, answer the polling and pretest questions, view the CE content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or CPE Statement of Credit. Pharmacist learners who submit their NABP and DOB will be reported to the CPE Monitor by Vindico Medical Education directly within 45 days.

Statement of Commercial Support

This activity is supported by an educational grant from ViiV Healthcare. ViiV Healthcare was not involved in the development of content or selection of faculty for this educational activity.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 ABIM MOC Point(s)
1.0 ACPE Contact Hour(s)
Released: March 15, 2022
Expires: March 14, 2023
60 minutes to complete

Accredited By

This continuing education activity is provided by

Target Audience

The intended audience for the activity is family medicine physicians, internists, pharmacists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients at high risk for acquiring HIV.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Evaluate complications of untreated HIV as well as the tools for risk assessments and routine screening.
  • Identify patient eligibility and the categories of patients who may benefit from pre-exposure prophylaxis (PrEP).
  • Review the latest clinical evidence regarding current and emerging PrEP therapies, including guidance on medication adherence and risk-reduction counseling.

Activity Description

HIV is a disease that attacks the body’s immune system. Patients with HIV have the capability to transmit the virus to other patients via either sex or sharing of needles or syringes. If HIV is not treated, it can lead to AIDS, which is the most severe phase of HIV infection. Because there is no effective vaccine to prevent HIV transmission, behavioral and biomedical HIV prevention strategies are needed to reduce HIV acquisition. For HIV-uninfected patients, PrEP using antiretroviral medications is an evidence-based method to prevent new infections among those at greatest risk, as data have shown that it is highly effective in individuals who are adherent to taking the PrEP agent. In this CE activity, the faculty for this program will identify the categories of patients who may benefit from PrEP, as well as explore the safety and efficacy of current PrEP therapies, and will utilize the unique ArcheMedX Intelligent Learning Platform.

Statement of Educational Need

Several quality care gaps exist when managing individuals who are at high risk for developing HIV. This insufficient care is attributed to numerous factors, including primary care physicians and other providers who do not perform routine screenings and risk assessments of patients, do not discuss PrEP or any other risk prevention strategies with patients who may exhibit high-risk behaviors, do not actively promote adherence to PrEP or follow up with patients, and who lack competence about current PrEP therapies. As such, an educational initiative discussing these topics is warranted to improve outcomes for patients who are at high risk for acquiring HIV.

Agenda

Introduction - David A. Wohl, MD

Burden of HIV and Tools for Risk Assessment - Latesha Elopre, MD, MSPH

PrEP Therapies and Adherence Strategies - David A. Wohl, MD

Case Presentation & Panel Discussion - All Faculty

Activity Chair

David A. Wohl, MD
Professor of Medicine
Division of Infectious Diseases
University of North Carolina at Chapel Hill School of Medicine
Chapel Hill, NC

Disclosure:
Advisor: Gilead, Merck, ViiV
Consultant: Gilead, Merck, ViiV
Independent Research Contractor: Gilead, Merck, ViiV

Faculty

Latesha Elopre, MD, MSPH
Associate Professor
Division of Infectious Diseases
University of Alabama at Birmingham
Birmingham, AL

Disclosure: No relevant financial relationships to disclose.

Planners/Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Jennifer Cocohoba, PharmD, MAS, BCPS, AAHIVP
Disclosure:
Independent Research Contractor: Actelion/Janssen, ViiV

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Accreditation Council for Pharmacy EducationVindico Medical Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Successful completion of this CME activity enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in by providing their ABIM ID and DOB (MM/DD) will earn MOC points equivalent to the amount of CME credits claimed for the activity.

This program is acceptable for 1.0 contact hour of ACPE Continuing Education Credit. The ACPE Universal Program Number 0482-0000-22-002-H02-P, effective 03/15/2022. This is a knowledge-based activity, and there is no fee to attend.

Vindico Medical Education will provide pharmacist credits claimed information directly to the ACPE through CPE Monitor within 45 days.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.

Physician assistants participating in the activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

This enduring material is approved for 1 year from the date of original release, March 15, 2022 to March 14, 2023.

Instructions for Receiving Credit

To participate in this CE activity, you must read the objectives, answer the polling and pretest questions, view the CE content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or CPE Statement of Credit. Pharmacist learners who submit their NABP and DOB will be reported to the CPE Monitor by Vindico Medical Education directly within 45 days.

Statement of Commercial Support

This activity is supported by an educational grant from ViiV Healthcare. ViiV Healthcare was not involved in the development of content or selection of faculty for this educational activity.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Julia B. García-Díaz, MD, MSc, FACP, FIDSA, CPI
0.25 CME / MOC / CNE / IPCE
RMEI Medical Education, LLC
Challenging Cases of Severe COVID-19: Managing High Risk and Unvaccinated Patients

Challenging Cases of Severe COVID-19: Managing High Risk and Unvaccinated Patients

Start

Activity Details

Free CME/CNE/IPCE/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 ANCC Contact Hour(s)
0.25 IPCE Credit(s)™
0.25 ABIM MOC Point(s)
Released: February 28, 2022
Expires: February 27, 2023
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for emergency medicine, hospital medicine, infectious disease, internal medicine, and pediatric clinicians (MD/NP/PA/Nurses) involved in the treatment of patients with severe COVID-19 infection.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Incorporate emergency use authorization status and available clinical trial data into the selection of treatment for patients hospitalized with COVID-19 
  • Integrate the unique roles and responsibilities of interprofessional care team members in the management of severe COVID-19 in hospitalized patients

Activity Description

In this activity, an interprofessional panel discusses 2 real-world cases of severe COVID-19 submitted by our learners and offers their insight on how to best approach their care.

Chair

Julia B. García-Díaz, MD, MSc, FACP, FIDSA, CPI
Director, Clinical Infectious Diseases Research and MultiSpecialties
Clinical Associate Professor, Medicine (Tulane University)
Associate Professor, University of Queensland/Ochsner Clinical School, Brisbane, Australia
Ochsner Health
New Orleans, LA


Faculty

Thomas F. Patterson, MD, FACP, FIDSA
Chief, Division of Infectious Diseases
Vice-Chair, Faculty Development
Professor, Medicine
Director, San Antonio Center for Medical Mycology
UT Health San Antonio
San Antonio, TX


Fiona A. Winterbottom, DNP, MSN, APRN, ACNS-BC, ACHPN, CCRN
Advanced Practice Provider, Pulmonary Critical Care
Chairperson, System Critical Care Integration Council
Ochsner Medical Center
Ochsner Health
New Orleans, LA


Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Julia B. García-Díaz, MD, MSc, FACP, FIDSA, CPI,
has no relevant financial relationships with ineligible companies to disclose.

Thomas F. Patterson, MD, FACP, FIDSA, has relevant financial relationships with Appili, Basilea, Gilead, Mayne, Merck, Pfizer, Scynexis, Sfunga (Consultant); Cidara, F2G (Researcher).

Fiona A. Winterbottom, DNP, MSN, APRN, ACNS-BC, ACHPN, CCRN, has relevant financial relationships with Baxter (Advisor); Zoll (Speaker/Speaker’s Bureau).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.


Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 100% on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

Physicians claiming ABIM MOC points must provide ABIM ID and month/date of birth and score 100% on the post-test.

For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/CNE/IPCE/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 ANCC Contact Hour(s)
0.25 IPCE Credit(s)™
0.25 ABIM MOC Point(s)
Released: February 28, 2022
Expires: February 27, 2023
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for emergency medicine, hospital medicine, infectious disease, internal medicine, and pediatric clinicians (MD/NP/PA/Nurses) involved in the treatment of patients with severe COVID-19 infection.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Incorporate emergency use authorization status and available clinical trial data into the selection of treatment for patients hospitalized with COVID-19 
  • Integrate the unique roles and responsibilities of interprofessional care team members in the management of severe COVID-19 in hospitalized patients

Activity Description

In this activity, an interprofessional panel discusses 2 real-world cases of severe COVID-19 submitted by our learners and offers their insight on how to best approach their care.

Chair

Julia B. García-Díaz, MD, MSc, FACP, FIDSA, CPI
Director, Clinical Infectious Diseases Research and MultiSpecialties
Clinical Associate Professor, Medicine (Tulane University)
Associate Professor, University of Queensland/Ochsner Clinical School, Brisbane, Australia
Ochsner Health
New Orleans, LA


Faculty

Thomas F. Patterson, MD, FACP, FIDSA
Chief, Division of Infectious Diseases
Vice-Chair, Faculty Development
Professor, Medicine
Director, San Antonio Center for Medical Mycology
UT Health San Antonio
San Antonio, TX


Fiona A. Winterbottom, DNP, MSN, APRN, ACNS-BC, ACHPN, CCRN
Advanced Practice Provider, Pulmonary Critical Care
Chairperson, System Critical Care Integration Council
Ochsner Medical Center
Ochsner Health
New Orleans, LA


Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Julia B. García-Díaz, MD, MSc, FACP, FIDSA, CPI,
has no relevant financial relationships with ineligible companies to disclose.

Thomas F. Patterson, MD, FACP, FIDSA, has relevant financial relationships with Appili, Basilea, Gilead, Mayne, Merck, Pfizer, Scynexis, Sfunga (Consultant); Cidara, F2G (Researcher).

Fiona A. Winterbottom, DNP, MSN, APRN, ACNS-BC, ACHPN, CCRN, has relevant financial relationships with Baxter (Advisor); Zoll (Speaker/Speaker’s Bureau).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.


Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 100% on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

Physicians claiming ABIM MOC points must provide ABIM ID and month/date of birth and score 100% on the post-test.

For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Pages